Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
How CRISPR gene editing will treat diseases in future: Nobel-winning Intellia co-founder Jennifer Doudna
10:04am, Wednesday, 30'th Jun 2021
Jennifer Doudna, 2020 Nobel Prize winner in chemistry for CRISPR gene editing and co-founder of Intellia Therapeutics, on future of the breakthrough technology.
Implied Volatility Surging for Intellia Therapeutics (NTLA) Stock Options
09:33am, Wednesday, 30'th Jun 2021
Investors need to pay close attention to Intellia Therapeutics (NTLA) stock based on the movements in the options market lately.
Intellia Therapeutics Stock Moves Higher After Capital Raise Of $600M Issued At $145/Share
07:11am, Wednesday, 30'th Jun 2021
Intellia Therapeutics Inc (NASDAQ: NTLA) has priced a previously announced public offering at $145 per share, representing a discount of 4.4% from the last close price of $151.6 on Tuesday. The com
Can Intellia Therapeutics Turn Exciting Trial Results into Profits?
06:47am, Wednesday, 30'th Jun 2021
New proof-of-concept results are a big deal for the medical community, but what about for your portfolio?
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
09:08pm, Tuesday, 29'th Jun 2021
CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/
This Could Be the Biggest Advancement in Healthcare in Years
04:31pm, Tuesday, 29'th Jun 2021
There's lots of good news to talk about today, but one of the biggest stories came from a major healthcare play. Let's dive in.
Intellia (NTLA) Up on Positive Gene-Editing Drug Interim Data
12:09pm, Tuesday, 29'th Jun 2021
Intellia (NTLA) posts positive interim data from phase I study on lead genome-editing candidate NTLA-2001 being developed for treating transthyretin (ATTR) amyloidosis. Stock up.
3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data
10:39am, Tuesday, 29'th Jun 2021
Intellia (NTLA) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy. Stocks of CRSP, EDIT and BEAM rise on investor enthusiasm about their CRISPR-based candidates.
Intellia Therapeutics Analyst Doubles Price Target: What You Need To Know
05:05pm, Monday, 28'th Jun 2021
An SVB Leerink genetic medicine analyst is bullish on shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA). Here's why.
Intellia Makes History. Can It Deliver A Cure?
04:43pm, Monday, 28'th Jun 2021
Intellia stunned the medical community with their Phase 1 interim results.
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 28'th Jun 2021
CAMBRIDGE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/
Cathie Wood's Ark ETFs are surging on big gains in CRISPR gene-editing stocks following the success of first human trials
03:58pm, Monday, 28'th Jun 2021
Ark Invest's Cathie Wood said last year that the next "FANG" stocks would likely come from the gene editing space.
Intellia Makes a Splash, Bringing Other CRISPR Stocks Along for the Ride
01:45pm, Monday, 28'th Jun 2021
As a result of this news, NTLA stock is way up, and other genome editing stocks are seeing gains as well. The post Intellia Makes a Splash, Bringing Other CRISPR Stocks Along for the Ride appeared fir
Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money
01:17pm, Monday, 28'th Jun 2021
Find out why these stocks are climbing higher.
Intellia soars on trial results using CRISPR technology
12:06pm, Monday, 28'th Jun 2021
CNBC's Meg Tirrell reports on the promising results from a trial using CRISPR gene-editing technology, which sent shares of Intellia higher.
